334 related articles for article (PubMed ID: 25630937)
1. Oncolytic parvoviruses: from basic virology to clinical applications.
Marchini A; Bonifati S; Scott EM; Angelova AL; Rommelaere J
Virol J; 2015 Jan; 12():6. PubMed ID: 25630937
[TBL] [Abstract][Full Text] [Related]
2. A Roadmap for the Success of Oncolytic Parvovirus-Based Anticancer Therapies.
Hartley A; Kavishwar G; Salvato I; Marchini A
Annu Rev Virol; 2020 Sep; 7(1):537-557. PubMed ID: 32600158
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic parvoviruses as cancer therapeutics.
Rommelaere J; Geletneky K; Angelova AL; Daeffler L; Dinsart C; Kiprianova I; Schlehofer JR; Raykov Z
Cytokine Growth Factor Rev; 2010; 21(2-3):185-95. PubMed ID: 20211577
[TBL] [Abstract][Full Text] [Related]
4. LuIII parvovirus selectively and efficiently targets, replicates in, and kills human glioma cells.
Paglino JC; Ozduman K; van den Pol AN
J Virol; 2012 Jul; 86(13):7280-91. PubMed ID: 22553327
[TBL] [Abstract][Full Text] [Related]
5. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
Bretscher C; Marchini A
Viruses; 2019 Jun; 11(6):. PubMed ID: 31216641
[TBL] [Abstract][Full Text] [Related]
6. [Oncolytic parvoviruses. A new approaches for cancer therapy].
Loktev VB; Ivan'kina TIu; Netesov SV; Chumakov PM
Vestn Ross Akad Med Nauk; 2012; (2):42-7. PubMed ID: 22642177
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial.
Geletneky K; Hajda J; Angelova AL; Leuchs B; Capper D; Bartsch AJ; Neumann JO; Schöning T; Hüsing J; Beelte B; Kiprianova I; Roscher M; Bhat R; von Deimling A; Brück W; Just A; Frehtman V; Löbhard S; Terletskaia-Ladwig E; Fry J; Jochims K; Daniel V; Krebs O; Dahm M; Huber B; Unterberg A; Rommelaere J
Mol Ther; 2017 Dec; 25(12):2620-2634. PubMed ID: 28967558
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.
Angelova AL; Barf M; Geletneky K; Unterberg A; Rommelaere J
Viruses; 2017 Dec; 9(12):. PubMed ID: 29244745
[TBL] [Abstract][Full Text] [Related]
9. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid.
Allaume X; El-Andaloussi N; Leuchs B; Bonifati S; Kulkarni A; Marttila T; Kaufmann JK; Nettelbeck DM; Kleinschmidt J; Rommelaere J; Marchini A
J Virol; 2012 Apr; 86(7):3452-65. PubMed ID: 22258256
[TBL] [Abstract][Full Text] [Related]
10. Immune System Stimulation by Oncolytic Rodent Protoparvoviruses.
Angelova A; Rommelaere J
Viruses; 2019 May; 11(5):. PubMed ID: 31060205
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment.
Nüesch JP; Lacroix J; Marchini A; Rommelaere J
Clin Cancer Res; 2012 Jul; 18(13):3516-23. PubMed ID: 22566376
[TBL] [Abstract][Full Text] [Related]
12. Virotherapy of digestive tumors with rodent parvovirus: overview and perspectives.
Akladios C; Aprahamian M
Expert Opin Biol Ther; 2016; 16(5):645-53. PubMed ID: 26855087
[TBL] [Abstract][Full Text] [Related]
13. [Oncolytic properties of some orthopoxviruses, adenoviruses and parvoviruses in human glioma cells].
Razumov IA; Sviatchenko VA; Protopopova EV; Kochneva GV; Kiselev NN; Gubanova NV; Shilov AG; Mordvinov VA; Netesov SV; Chumakov PM; Loktev VB
Vestn Ross Akad Med Nauk; 2013; (12):4-8. PubMed ID: 24741936
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo.
Lacroix J; Kis Z; Josupeit R; Schlund F; Stroh-Dege A; Frank-Stöhr M; Leuchs B; Schlehofer JR; Rommelaere J; Dinsart C
Viruses; 2018 Jun; 10(6):. PubMed ID: 29865280
[TBL] [Abstract][Full Text] [Related]
15. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
[TBL] [Abstract][Full Text] [Related]
16. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.
Raykov Z; Grekova S; Galabov AS; Balboni G; Koch U; Aprahamian M; Rommelaere J
Oncol Rep; 2007 Jun; 17(6):1493-9. PubMed ID: 17487410
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies.
Angelova AL; Aprahamian M; Balboni G; Delecluse HJ; Feederle R; Kiprianova I; Grekova SP; Galabov AS; Witzens-Harig M; Ho AD; Rommelaere J; Raykov Z
Mol Ther; 2009 Jul; 17(7):1164-72. PubMed ID: 19367260
[TBL] [Abstract][Full Text] [Related]
18. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.
Geletneky K; Hartkopf AD; Krempien R; Rommelaere J; Schlehofer JR
J Biomed Biotechnol; 2010; 2010():350748. PubMed ID: 20224643
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence In Situ Hybridization (FISH) Detection of Viral Nucleic Acids in Oncolytic H-1 Parvovirus-Treated Human Brain Tumors.
Kiprianova I; Just A; Leuchs B; Rommelaere J; Angelova AL
Methods Mol Biol; 2020; 2058():295-306. PubMed ID: 31486047
[TBL] [Abstract][Full Text] [Related]
20. Atomic Resolution Structure of the Oncolytic Parvovirus LuIII by Electron Microscopy and 3D Image Reconstruction.
Pittman N; Misseldine A; Geilen L; Halder S; Smith JK; Kurian J; Chipman P; Janssen M; Mckenna R; Baker TS; D'Abramo A; Cotmore S; Tattersall P; Agbandje-McKenna M
Viruses; 2017 Oct; 9(11):. PubMed ID: 29084163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]